Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$17.77 +0.8%	$18.88	$13.52 ▼ $35.25	$1.80B	2.22	2.07 million shs	1.19 million shs
ETON Eton Pharmaceuticals	$16.95 +1.5%	$14.83	$3.96 ▼ $21.48	$454.44M	1.13	369,223 shs	227,791 shs
SRPT Sarepta Therapeutics	$21.70 +6.9%	$20.17	$10.41 ▼ $144.22	$2.12B	0.46	6.12 million shs	6.24 million shs
VCEL Vericel	$35.53 -0.7%	$39.86	$33.09 ▼ $63.00	$1.79B	1.27	499,201 shs	319,123 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	+0.63%	-1.29%	-9.96%	-1.45%	-24.53%
ETON Eton Pharmaceuticals	-2.45%	+9.44%	+15.73%	-11.78%	+311.33%
SRPT Sarepta Therapeutics	-0.34%	+13.03%	+11.48%	-44.28%	-84.75%
VCEL Vericel	-5.69%	-1.05%	-3.58%	-15.80%	-21.05%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BEAM Beam Therapeutics	2.3037 of 5 stars	3.5	0.0	0.0	2.9	2.5	0.6
ETON Eton Pharmaceuticals	2.3236 of 5 stars	3.5	1.0	0.0	3.0	1.7	0.6
SRPT Sarepta Therapeutics	4.6129 of 5 stars	4.1	2.0	4.2	2.4	1.7	1.9
VCEL Vericel	2.3029 of 5 stars	3.5	0.0	0.0	3.0	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	3.07	Buy	$48.45	172.68% Upside
ETON Eton Pharmaceuticals	3.00	Buy	$29.67	75.08% Upside
SRPT Sarepta Therapeutics	2.10	Hold	$44.17	103.56% Upside
VCEL Vericel	3.00	Buy	$60.33	69.80% Upside

Current Analyst Ratings Breakdown

Latest ETON, VCEL, BEAM, and SRPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	SRPT Sarepta Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sell ➝ Sell	$6.00 ➝ $12.00
8/7/2025	SRPT Sarepta Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$19.00
8/7/2025	SRPT Sarepta Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$48.00 ➝ $50.00
8/6/2025	BEAM Beam Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$25.00 ➝ $21.00
8/1/2025	VCEL Vericel	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$61.00 ➝ $58.00
7/29/2025	SRPT Sarepta Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$22.00
7/29/2025	SRPT Sarepta Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
7/29/2025	SRPT Sarepta Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Perform ➝ Market Perform	$25.00 ➝ $50.00
7/29/2025	SRPT Sarepta Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $20.00
7/29/2025	SRPT Sarepta Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$15.00
7/29/2025	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$63.52M	28.30	N/A	N/A	$10.35 per share	1.72
ETON Eton Pharmaceuticals	$39.01M	11.65	N/A	N/A	$0.89 per share	19.04
SRPT Sarepta Therapeutics	$1.90B	1.11	$2.59 per share	8.37	$13.89 per share	1.56
VCEL Vericel	$237.22M	7.56	$0.29 per share	121.38	$6.08 per share	5.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$376.74M	-$4.50	N/A	N/A	N/A	-661.31%	-43.15%	-31.06%	N/A
ETON Eton Pharmaceuticals	-$3.82M	-$0.16	N/A	33.89	N/A	-7.10%	-0.73%	-0.22%	N/A
SRPT Sarepta Therapeutics	$235.24M	-$0.87	N/A	1.98	N/A	-2.34%	-1.03%	-0.37%	N/A
VCEL Vericel	$10.36M	$0.12	296.12	80.75	N/A	2.85%	2.47%	1.69%	N/A

Latest ETON, VCEL, BEAM, and SRPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	ETON Eton Pharmaceuticals	-$0.01	-$0.10	-$0.09	-$0.10	$16.71 million	$18.93 million
8/6/2025	Q2 2025	SRPT Sarepta Therapeutics	$0.89	$2.02	+$1.13	$1.89	$530.66 million	$611.09 million
8/5/2025	Q2 2025	BEAM Beam Therapeutics	-$1.04	-$1.00	+$0.04	-$1.00	$13.29 million	$8.47 million
7/31/2025	Q2 2025	VCEL Vericel	-$0.04	-$0.01	+$0.03	-$0.01	$64.61 million	$63.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	N/A	6.75	6.75
ETON Eton Pharmaceuticals	1.14	1.77	1.16
SRPT Sarepta Therapeutics	0.84	2.89	1.81
VCEL Vericel	N/A	4.97	4.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
ETON Eton Pharmaceuticals	27.86%
SRPT Sarepta Therapeutics	86.68%
VCEL Vericel	N/A

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.50%
ETON Eton Pharmaceuticals	16.03%
SRPT Sarepta Therapeutics	7.60%
VCEL Vericel	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	101.16 million	97.62 million	Optionable
ETON Eton Pharmaceuticals	20	26.82 million	22.52 million	Optionable
SRPT Sarepta Therapeutics	1,372	97.71 million	90.29 million	Optionable
VCEL Vericel	300	50.46 million	47.84 million	Optionable

ETON, VCEL, BEAM, and SRPT Headlines

Recent News About These Companies

Townsquare Capital LLC Purchases 7,312 Shares of Vericel Corporation (NASDAQ:VCEL)

August 13 at 4:25 AM | marketbeat.com

Vericel (VCEL) Receives a Buy from Canaccord Genuity

August 12 at 9:08 PM | theglobeandmail.com

Global Alpha Capital Management Ltd. Boosts Stock Holdings in Vericel Corporation (NASDAQ:VCEL)

August 10, 2025 | marketbeat.com

Zions Bancorporation National Association UT Makes New Investment in Vericel Corporation (NASDAQ:VCEL)

August 10, 2025 | marketbeat.com

CenterBook Partners LP Invests $888,000 in Vericel Corporation (NASDAQ:VCEL)

August 9, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Shares Purchased by Mutual of America Capital Management LLC

August 8, 2025 | marketbeat.com

Vericel Q2 Revenue Jumps 20%

August 5, 2025 | fool.com

Vericel Corporation (NASDAQ:VCEL) Short Interest Up 308.4% in July

August 5, 2025 | americanbankingnews.com

Vericel FY2025 EPS Forecast Decreased by Leerink Partnrs

August 5, 2025 | americanbankingnews.com

Vericel Corporation (NASDAQ:VCEL) Shares Purchased by Geneva Capital Management LLC

August 4, 2025 | marketbeat.com

FY2025 EPS Estimates for Vericel Decreased by Analyst

August 4, 2025 | marketbeat.com

Vericel (NASDAQ:VCEL) Posts Earnings Results, Beats Estimates By $0.03 EPS

August 3, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Short Interest Update

August 3, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Shares Sold by Baker Avenue Asset Management LP

August 3, 2025 | marketbeat.com

Vericel (NASDAQ:VCEL) Price Target Cut to $58.00 by Analysts at Canaccord Genuity Group

August 2, 2025 | marketbeat.com

Vericel (NASDAQ:VCEL) Hits New 52-Week Low - Here's What Happened

August 2, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Q2 2025 Earnings Call Transcript

August 2, 2025 | msn.com

Vericel Corporation Reports Strong Q2 2025 Earnings

August 1, 2025 | tipranks.com

Vericel (NASDAQ:VCEL) Shares Gap Down - Here's What Happened

August 1, 2025 | marketbeat.com

Earnings To Watch: Vericel Corp (VCEL) Reports Q2 2025 Result

August 1, 2025 | finance.yahoo.com

Vericel Corporation (VCEL) Q2 2025 Earnings Call Transcript

August 1, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ETON, VCEL, BEAM, and SRPT Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$17.77 +0.14 (+0.79%)

As of 02:48 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Eton Pharmaceuticals NASDAQ:ETON

$16.94 +0.25 (+1.47%)

As of 02:48 PM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Sarepta Therapeutics NASDAQ:SRPT

$21.70 +1.40 (+6.88%)

As of 02:48 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Vericel NASDAQ:VCEL

$35.53 -0.24 (-0.67%)

As of 02:48 PM Eastern

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time